Log in to search using one of your social media accounts:

 

How a tumor grows can predict response to cancer therapy

(University of Southern California) Individual tumors respond differently to cancer drugs, if at all. Until now, it remained a mystery why tumors have different reactions to the exact same therapy. But a new study at the USC Viterbi School of Engineering finds that tumor growth properties can influence response to cancer drugs.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Spermidine‑induced growth inhibition and apoptosis via autophagic activation in cervical cancer. Oncol Rep. 2018 Apr 18;: Authors: Chen Y, Zhuang H, Chen X, Shi Z, Wang X Abstract Cervical cancer is the most common malignancy of the female reproductive tract, and the poor response to prophylactic vaccines and the toxicity of high‑dose chemotherapeutic drugs have limited their clinical application. Spermidine, a natural polyamine detected in all eukaryotic organisms, exhibits functions that promote longevity in multiple model systems and may constitute a promising agent for cancer treatment. However...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Hu Q, Song J, Ding B, Cui Y, Liang J, Han S Abstract Cervical cancer is the third most common type of cancer in women, and microRNAs play an important role in this type of cancer. The elevated expression of miR-146a is involved in the pathogenesis of cancers generally, but its role in cervical cancer has not been fully elucidated. In the present study, we assessed the expression of miR-146a in G>C polymorphisms and confirmed that the overexpression of miR-146a promoted cervical cancer cell viability. The recombinant expression plasmids pre-miR-146a-G or pre-miR-146a-C including single nucleotide polymor...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
The National Cancer InstituteLaboratory of Molecular Biologyseeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.  There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC).   Glypican-3 (GPC3) is a cell surface heparin sulfate glycoprotein that is expressed on the vast majority of HCC cells. The correlation between GPC3 expression and HCC makes GPC3 an attractive candidate for studying the disease progression and treatment of HCC. The presence, ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, primarily tumor infiltrating lymphocytes (TIL), is selected and expanded to large quantities, it gets re-infused into the patient via an adoptive cell transfer (ACT) regimen. The key finding for this process is that the most tumor...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Nitroxyl (HNO) has recently emerged as a prospective pharmacological agent.   Studies of the chemistry of HNO have led to an understanding that HNO is vastly different from nitric oxide (NO). HNO displays unique cardiovascular properties and has been shown to have positive effects in failing hearts without changing heart rate, and also has been shown to have beneficial eff ects in ischemia reperfusion injury.  In addition to the observed cardiovascular effects, HNO has shown initial promise in the realm of cancer therapy. HNO has been demonstrated to inhibit a key glycolytic enzyme. Due to the Warburg effect, inh...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSION: The results from this study emphasize the promise of PTE in cancer therapy. PMID: 29687285 [PubMed - as supplied by publisher]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
This study demonstrates that localized doxorubicin delivery to the brain can be facilitated by TSL-Dox with localized hyperthermia with no significant neurological deficits. PMID: 29688083 [PubMed - in process]
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
In this issue of Oncology Scan, similar to previous head and neck cancer Oncology Scans (1-7), we examine the use of genomic signatures to predict response to head and neck cancer therapy (8-10). In the past decade and a half, multiple teams have identified and developed gene expression profile signatures capable of subclassifying head and neck cancer, prognosticating outcome, and predicting treatment response. We discuss the implications of these genomic signatures for head and neck cancer patients, how these signatures can be applied to other therapies, their use to assist in preclinical studies, and suggestions on how t...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Feature Source Type: research
AbstractThe advent of multifunctional nanoparticle has enabled numerous innovative strategies in diagnostics, imaging, and cancer therapy. Despite the intense research efforts in developing new nanoparticles and surface bonding ligands, one major obstacle in achieving highly effective treatment, including minimizing detrimental side effects, is the inability to deliver drug-carrying nanoparticles from the injection point directly to the tumor site. The present study seeks to employ adirect nanodrug delivery methodology to feed multifunctional nanoparticles directly to tumor vasculatures, sparing healthy tissue. An importan...
Source: Medical and Biological Engineering and Computing - Category: Biomedical Engineering Source Type: research
Breast cancer therapy and cardiac mortality, Published online: 26 April 2018; doi:10.1038/s41569-018-0018-8Breast cancer therapy and cardiac mortality
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Study